Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
Simoes, Catia; Chillón, María Carmen; Martínez-Cuadrón, David; Calasanz, María José; Vidriales, María-Belén; Vázquez, Iria; Hernández-Ruano, Montserrat; Ariceta, Beñat; Aguirre-Ruiz, Paula; Burgos, Leire; Alignani, Diego; Villar, Sara; Alfonso, Ana; Prosper, Felipe; Ayala, Rosa; Martínez-López, Joaquín; Bergua Burgués, Juan Miguel; Vives, Susana; Pérez-Simón, José Antonio; [et al.]Fecha
2023-01-10Derechos
© 2022 by The American Society of Hematology. Licensed under Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0),
permitting only noncommercial, nonderivative use with attribution. All other rights
reserved.
Publicado en
Blood advances, 2023, 7(1), 167-173
Editorial
American Society of Hematology
Enlace a la publicación
Resumen/Abstract
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workup. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly-diagnosed AML patients. Presence of dysplasia according to MFC and WHO criteria had no prognostic value in the elderly. NGS of dysplastic cells and blasts isolated at diagnosis identified three evolutionary patterns: stable (n=12/21), branching (n=4/21) and clonal evolution (n=5/21). In patients achieving complete response, integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in approximately 80% of newly diagnosed AML patients, using techniques other than single-cell multiomics.
Colecciones a las que pertenece
- D22 Artículos [1134]